No Data
No Data
Arovella Therapeutics' ALA-101-onCARlytics Collaboration With Imugene Ends; Shares Down 12%
Arovella Therapeutics (ASX:ALA) said its collaboration with Imugene (ASX:IMU) to combine ALA‐101 and onCARlytics has ended, effective immediately, according to a Wednesday filing with the Australian S
Imugene's Phase 1 OnCARlytics Trial to Commence Combination Arm Treatment
Immuno-oncology company Imugene (ASX:IMU) said phase 1 clinical trial of CD19 oncolytic virotherapy drug candidate onCARlytics is scheduled to commence combination dosing solid tumor patients with CD1
Imugene's OnCARlytics Clears Phase 1 Milestone in Solid Tumour Therapy Trial
Clinical stage immuno-oncology company Imugene (ASX: IMU) has confirmed that a Phase 1 clinical trial of lead drug candidate onCARlytics has cleared its first cohort within the intra-tumoural monotherapy arm of the study.
Imugene Widens Per-Share Loss in H1 FY24 to AU$0.01 on Higher General, R&D Spending
Imugene (ASX:IMU) reported Thursday that it widened its loss per share in the six-month period ended Dec. 31, 2023, to AU$0.0100, versus the prior-year period's AU$0.0028. The immunotherapy developer
Imugene Reports H1 FY24 Loss Widens as Expenses Grow
05:54 PM EST, 02/28/2024 (MT Newswires) -- Imugene Reports H1 FY24 Loss Widens as Expenses Grow Price (AUD): $0.12, Change: $0.00, Percent Change: +4.35%
Why Are ASX Tech Shares Booming on Friday?
It's been a fairly lucrative day for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares so far this Friday.
No Data
Peterson111 : I would choose to always believe in mining stocks.
Wealthy Leio : It's gone down too much.